Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea
- Authors
- Choi, Sang-Eun; Brignone, Melanie; Cho, Seong Jin; Jeon, Hong Jin; Jung, Rangrhee; Campbell, Rosanne; Francois, Clement; Milea, Dominique
- Issue Date
- 10월-2016
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- Depression; antidepressant; cost-effectiveness; economic; model
- Citation
- EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, v.16, no.5, pp.629 - 638
- Indexed
- SCIE
SSCI
SCOPUS
- Journal Title
- EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
- Volume
- 16
- Number
- 5
- Start Page
- 629
- End Page
- 638
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/87310
- DOI
- 10.1586/14737167.2016.1128830
- ISSN
- 1473-7167
- Abstract
- Objective: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea.Methods: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states.Results: Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations.Conclusion: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Pharmacy > Department of Pharmaceutical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.